Completed PHASE2 INTERVENTIONAL 1-arm NCT06425055

Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1) (ALPESTRIA-1)

Vonafexor Fixed Dose-escalation Safety and Proof-of-concept Study in Patients With at Risk of Progression Alport Syndrome

Sponsor: Enyo Pharma

Conditions Alport Syndrome

Interventions Vonafexor

Updated 10 times since 2024 Last updated: Feb 6, 2026 Started: Aug 1, 2024 Primary completion: Sep 4, 2025 Completion: Nov 20, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Alport Syndrome and is currently completed. Enyo Pharma leads this study, which shows 10 recorded versions since 2024 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

10 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Sep 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE2
May 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE2
Feb 2025 — May 2025 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Dec 2024 — Feb 2025 [monthly]

Recruiting PHASE2

▶ Show 5 earlier versions

Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE2
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jun 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Enyo Pharma

Data source: Enyo Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Birmingham, United States , Boise, United States , Bordeaux, France , Cleveland, United States , Dallas, United States , El Palmar, Spain , Hinsdale, United States , Los Angeles, United States , Madrid, Spain and 3 more locations